AR091908A1 - COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS - Google Patents

COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS

Info

Publication number
AR091908A1
AR091908A1 ARP130102660A ARP130102660A AR091908A1 AR 091908 A1 AR091908 A1 AR 091908A1 AR P130102660 A ARP130102660 A AR P130102660A AR P130102660 A ARP130102660 A AR P130102660A AR 091908 A1 AR091908 A1 AR 091908A1
Authority
AR
Argentina
Prior art keywords
benzene
preparation
methods
glucopiranos
ciclopropil
Prior art date
Application number
ARP130102660A
Other languages
English (en)
Inventor
Martin Hans
Juergen-Himmelsbach Frank
Butz Tanja
Eckhardt Matthias
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR091908A1 publication Critical patent/AR091908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un complejo cristalino de 1-ciano-2-(4-ciclopropil-bencil)-4-(b-D-glucopiranos-1-il)-benceno y uno o varios aminoácidos naturales, métodos para su preparación así como sus usos para preparar medicamentos.
ARP130102660A 2012-07-26 2013-07-25 COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS AR091908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
AR091908A1 true AR091908A1 (es) 2015-03-11

Family

ID=48874313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102660A AR091908A1 (es) 2012-07-26 2013-07-25 COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS

Country Status (23)

Country Link
US (1) US9145434B2 (es)
EP (3) EP2877460B1 (es)
JP (2) JP6538556B2 (es)
CN (2) CN104470908A (es)
AR (1) AR091908A1 (es)
AU (1) AU2013294947B2 (es)
BR (1) BR112015001327B1 (es)
CA (1) CA2878698C (es)
DK (2) DK2877460T3 (es)
EA (2) EA025438B1 (es)
ES (2) ES2937665T3 (es)
FI (1) FI3351539T3 (es)
HR (2) HRP20181972T1 (es)
HU (1) HUE061450T2 (es)
LT (1) LT3351539T (es)
MX (1) MX357906B (es)
PL (2) PL2877460T3 (es)
PT (2) PT2877460T (es)
RS (1) RS63881B1 (es)
SG (1) SG11201500574QA (es)
SI (2) SI2877460T1 (es)
TW (1) TW201418275A (es)
WO (1) WO2014016381A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
LT3862003T (lt) 2013-12-17 2023-12-27 Boehringer Ingelheim Vetmedica Gmbh Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams
EA032558B1 (ru) 2014-01-23 2019-06-28 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей собачьих
MX376911B (es) * 2014-04-01 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de sglt2 para usarse en el tratamiento de trastornos metabolicos en animales equinos.
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
EP3197429B1 (en) 2014-09-25 2024-05-22 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
WO2016050134A1 (zh) * 2014-09-30 2016-04-07 江苏恒瑞医药股份有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
EP3341024B1 (en) 2015-08-27 2024-10-09 Boehringer Ingelheim Vetmedica GmbH Liquid pharmaceutical compositions comprising sglt-2 inhibitors
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
US10793588B2 (en) 2016-05-28 2020-10-06 Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. Crystal form of sodium-glucose cotransporter 2 inhibitor
EP3668846A1 (en) 2017-12-19 2020-06-24 Boehringer Ingelheim Vetmedica GmbH Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN117715639A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
TW202412756A (zh) 2022-05-25 2024-04-01 德商百靈佳殷格翰維美迪加股份有限公司 包含sglt-2抑制劑之水性醫藥組合物
CN120857933A (zh) 2023-03-06 2025-10-28 勃林格殷格翰动物保健有限公司 用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统
WO2024223388A1 (en) 2023-04-24 2024-10-31 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536047A (ja) * 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2512389A1 (en) * 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Methods of producing c-aryl glucoside sglt2 inhibitors
CN103030617A (zh) * 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
CA2621314A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
CN101468976B (zh) * 2007-12-27 2013-11-20 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
EP2324002B1 (en) * 2008-08-22 2016-10-05 Theracos Sub, LLC Processes for the preparation of sglt2 inhibitors
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych

Also Published As

Publication number Publication date
BR112015001327A2 (pt) 2017-07-04
MX2015000962A (es) 2015-04-16
EP3351539A1 (en) 2018-07-25
MX357906B (es) 2018-07-30
FI3351539T3 (fi) 2023-02-19
BR112015001327B1 (pt) 2022-08-16
EA201500038A1 (ru) 2015-07-30
HUE061450T2 (hu) 2023-07-28
TW201418275A (zh) 2014-05-16
WO2014016381A1 (en) 2014-01-30
CN104470908A (zh) 2015-03-25
EA201600506A1 (ru) 2017-03-31
RS63881B1 (sr) 2023-02-28
PT2877460T (pt) 2018-12-19
CA2878698A1 (en) 2014-01-30
LT3351539T (lt) 2023-02-10
ES2694675T3 (es) 2018-12-26
SI3351539T1 (sl) 2023-03-31
CN108774200A (zh) 2018-11-09
AU2013294947A1 (en) 2015-01-22
HRP20181972T1 (hr) 2019-01-25
US20140031540A1 (en) 2014-01-30
US9145434B2 (en) 2015-09-29
SG11201500574QA (en) 2015-02-27
HRP20230081T1 (hr) 2023-03-17
DK2877460T3 (en) 2019-01-07
PL3351539T3 (pl) 2023-03-06
ES2937665T3 (es) 2023-03-30
CA2878698C (en) 2021-03-23
DK3351539T3 (da) 2023-01-30
SI2877460T1 (sl) 2018-12-31
AU2013294947B2 (en) 2017-03-30
EP3351539B1 (en) 2022-11-09
JP2018135384A (ja) 2018-08-30
JP2015522644A (ja) 2015-08-06
EP4166548A1 (en) 2023-04-19
PL2877460T3 (pl) 2019-04-30
EP2877460B1 (en) 2018-09-12
JP6538556B2 (ja) 2019-07-03
PT3351539T (pt) 2023-01-17
EP2877460A1 (en) 2015-06-03
EA025438B1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
AR091908A1 (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
CL2014002903A1 (es) Composición geopolimérica de aluminosilicato; método de preparacion y sus usos.
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
LT2776469T (lt) Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
DK3542843T3 (da) Engangsinjektionspen til flere anvendelser
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BR112014012681A8 (pt) polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
DK3777840T3 (da) Rna-formulering til immunterapi
CO7121320A2 (es) Anticuerpos anti-hla-b*27 y usos de estos
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
PL3073959T3 (pl) Zespól szczepiący do podawania szczepionki do młodej kury
MX386584B (es) Composiciones de liberación retardada de linaclotida.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
MX379476B (es) Derivados de manosa, un proceso para su preparación y sus usos como un fármaco.
CL2013002581A1 (es) Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios.
ITMI20132052A1 (it) Impianto di alimentazione di carburante e procedimento per farlo funzionare.
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
CL2013003206A1 (es) Uso de compuestos derivados de metil y etil-carboxamidas de trifluorometil-benzotiofenos, en metodos para promover el crecimiento de plantas.
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4

Legal Events

Date Code Title Description
FB Suspension of granting procedure